TRONTINEMAB
UNII N0GBZ1GWC2

Substance Identification & Data

This profile provides standardized clinical and technical data for Trontinemab, uniquely identified by the FDA Unique Ingredient Identifier (UNII) N0GBZ1GWC2.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2568868-35-7 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

N0GBZ1GWC2

CAS Registry Number

2568868-35-7

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

TRONTINEMAB

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C188602

National Cancer Institute reference terminology for clinical and research data.

INN ID

12120

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

KL-203

Identifier assigned by the United States Adopted Names Council.

Substance Type

Trontinemab

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Trontinemab. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Trontinemab

Common Names & Synonyms

Immunoglobulin G1 [156-glutamic acid,222-glutamic acid,363-cysteine,375-tryptophan,de-456-lysine], anti-(human β-amyloid 1-40/42) (human clone mAb31 γ1-chain) fusion protein with peptide linker (GGS(GGGGS)3) fusion protein with immunoglobulin anti-(human transferrin receptor 1) (human-Oryctolagus cuniculus clone BBB-1026 heavy chain V-D-J region) fusion protein with immunoglobulin [1-alanine,2-serine] (human κ-chain C region), disulfide with immunoglobulin [endo-111-serine,endo-112-serine] anti-(human transferrin receptor 1) (human-Oryctolagus cuniculus clone BBB-1026 κ-chain V-J region) fusion protein with immunoglobulin G1 (human γ1-chain CH1 region), (235→235'),(238→238'),(358→363')- tris(disulfide) with immunoglobulin G1 [156-glutamic acid,222-glutamic acid,358-cysteine,375-serine,377-alanine,416-valine] anti-(human β-amyloid 1-40/42) (human clone mAb31 γ1-chain), disulfide with immunoglobulin G1 [124-arginine,125-lysine] anti-(human β-amyloid 1-40/42) (human clone mAb31 κ-chain)

RECOMBINANT (2+1) BISPECIFIC HUMANIZED MONOCLONAL ANTI-A-BETA PEPTIDE AND BINDS TO TRANSFERRIN RECEPTOR (TFR).

TRONTINEMAB [USAN]

immunoglobulin [G1-VH-Ckappa_Vkappa-CH1]_[G1_kappa] with domain crossover, anti-[Homo sapiens APP (amyloid beta, A4 precursor protein) Abeta, conformational epitope 1-40/42)] and anti- [Homo sapiens TFRC (transferrin receptor, p90, CD71)], humanized monoclonal antibody, bispecific; fused chain G1-VH-Ckappa bispecific, anti-APP A beta and anti-TFRC (1-702) [gamma1 heavy chain anti-APP Abeta (1-455) humanized [VH (Homo sapiens IGHV3-23*04 (92.9%) -(IGHD) -IGHJ4*01 (93.3%), CDR-IMGT [8.8.19] (26-33.51-58.97-115)) (1-126) -Homo sapiens IGHG1*01, G1m17,1, G1v32 CH3 W22 (CH1 K26>E (156), K119>E (222), K120 (223) (127-224), hinge 1-15 (225-239), CH2 (240-349), CH3 S10>C (363), D12 (365), L14 (367), T22>W (375) (350-454), CHS K2>del (455)) (127-455)] -18-mer diglycyl-seryl-tris(tetraglycyl-seryl) linker (456-473) -VH-Ckappa chain anti-TFRC (474-702) humanized [VH (Homo sapiens IGHV4-31*02 (76.0%) -(IGHD) -IGHJ5*02 (100%), CDR-IMGT [8.7.19] (498-505.523-529.566-584)) (474-595) -alanylseryl (596-597) -C-KAPPA (Homo sapiens IGKC*01 (100%), Km3 A45.1 (641), V101 (679) (598-702)], (229-215''')-disulfide with kappa light chain anti-APP Abeta (1'''-215''') humanized [V-KAPPA (Homo sapiens IGKV3D-7*01 (89.6%) - IGKJ1*01 (100%), CDR-IMGT [7.3.9] (27-33.51-53.90-98)) (1'''-108''') - Homo sapiens IGKC*01 (100%), Km3 A45.1 (154), V101 (192), E12>R (124), Q13>K (125) (109'''-215''')], (702-215'''')-disulfide with Vkappa- CH1 chain anti-TFRC (1''''-215'''') humanized [V-KAPPA (Homo sapiens IGKV1-13*02 (94.4%) -IGKJ4*01 (100%), CDR-IMGT [6.3.12] (27- 32.50-52.89-100)) (1''''-110'''') -diseryl (111''''-112'''') -CH1-hinge (Homo sapiens IGHG1*01 CH1-h, G1m17 (CH1 K120 (209) (113''''-210''''), hinge 1-5 (211''''-215'''')) (113''''-215'''')], gamma1 heavy chain anti-APP Abeta (1''-456'') humanized [VH (Homo sapiens IGHV3-23*04 (92.9%) -(IGHD) -IGHJ4*01 (93.3%), CDR-IMGT [8.8.19] (26-33.51-58.97-115)) (1''-126'') -Homo sapiens IGHG1*01, G1m17,1, G1v33 CH3 S22, A24, V86 (CH1 K26>E (156), K119>E (222), K120 (223) (127''-224''), hinge 1-15 (225''-239''), CH2 (240''- 349''), CH3 Y5>C (358), D12 (365), L14 (367), T22>S (375), L24>A (377), Y86>V (416) (350''-454''), CHS (455''-456'')) (127''-456'')], (229''- 215''')-disulfide with kappa light chain anti-APP Abeta (1'''-215''') humanized [V-KAPPA (Homo sapiens IGKV3D-7*01 (89.6%) - IGKJ1*01 (100%), CDR-IMGT [7.3.9] (27-33.51-53.90-98)) (1'''-108''') - Homo sapiens IGKC*01 (100%), Km3 A45.1 (154), V101 (192) (109'''- 215''')], dimer (235-235'':238-238'':363-358'')-trisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

trontinemab [INN]